CLOs on the Move

CORE Ingredients and Packaging

www.coreingredients.com

 
CORE Ingredients & Packaging is a Opa Locka, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Footprints to Recovery

At Footprints to Recovery, our mission is to transform your life of addiction to a life of hope through inspiration, education, and support. We`re an individual focused and evidenced based addiction rehabilitation center, that emphasizes meaningful connections in recovery. We are conveniently located in Hamilton, NJ and Arlington Heights, IL.

IDS Limited

IDS Limited is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NexgenRx

NexgenRx is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Eastern Long Island Hospital

Eastern Long Island Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Greenport, NY. To find more information about Eastern Long Island Hospital, please visit www.elih.org

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.